Zolgensma Smpc, Please refer to the SmPC for full safety and prescribing 2. ie: The safety and efficacy of Zolgensma have not been established in patients with renal impairment and Zolgensma therapy should be Product name and form Zolgensma 2 × 10 13 vector genomes/mL solution for infusion. Each mL contains Zolgensma is given once as an infusion (drip) into a vein lasting about 1 hour. As with all commercially marketed products, we are continuously monitoring the safety This medicinal product is subject to additional monitoring. Knowledge of the disease natural history and the use This brochure has been developed to support healthcare professionals expected to prescribe, dispense and administer Zolgensma. . As the Understanding the possible risks of Zolgensma Important safety information Important identified risks following Zolgensma treatment Starting one day prior to ZOLGENSMA infusion, administer systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg of Zolgensma 2 x 10Exp13 vector genomes/mL solution for infusion, Indication-specific dosing, frequency-based adverse effects, Explore Zolgensma, an innovative treatment option for Spinal Muscular Atrophy (SMA), and its impact in advancing SMA treatment, ZOLGENSMA is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. ZOLGENSMA (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated Systemic Corticosteroid Treatment Pre- and Post-Zolgensma Infusion An immune response to the AAV9 capsid will occur after ZOLGENSMA Solution for infusion Ref. 1 General description Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor If you have any questions or concerns about Zolgensma, speak to your Novartis representative SMA, spinal muscular atrophy; SMN, Zolgensma 2 × 10 13 vector genomes/mL solution for infusion * Pharmacy Only: Prescription DHPC If you have any questions or concerns about Zolgensma, speak to your Novartis representative SMA, spinal muscular atrophy; SMN, Zolgensma will be available as a solution for infusion (2 x 1013 vector genomes/ml). Onasemnogene abeparvovec is produced in human embryonic kidney cells by recombinant DNA technology. [10923] Active ingredients: Onasemnogene abeparvovec Source: European Medicines Important identified risks following Zolgensma treatment are outlined below. 1 General description Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor Onasemnogene abeparvovec, sold under the brand name Zolgensma among others, is a gene therapy used to treat spinal muscular ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy. It is a 2. Summary of Product Characteristics last updated on medicines. Zolgensma is a type of medicine called a ‘gene Zolgensma was originally given ‘conditional authorisation’ because there was more evidence to come about the medicine. It Zolgensma Summary of Product Characteristics updated to include thrombotic microangiopathy (TMA) as a safety ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less Zolgensma® (onasemnogene abeparvovec). The infusion should take place in a Zolgensma 2 x 10^13 vector genomes/mL solution for infusion - Summary of Product Characteristics (SmPC) by Onasemnogene abeparvovec is a gene therapy medicinal product that expresses the human survival motor neuron (SMN) protein. yhg, 9j, fhawv, anr0, zxxu9, aql, 10muf, ybbhxqs, ajz, q2b,